Duke MMIL designs novel SPECT/CT system for 3D breast imaging

Jul 17, 2007
2007 07 17 14 38 39 706
2007 07 17 14 38 39 706
Image courtesy of Duke University Medical Center Multi-Modality Imaging Lab.

Latest in Molecular Imaging
Ctca
PET/CT can rule out CAV in heart transplant patients
January 17, 2025
New! Imaging Life Issue 20 now available
Sponsored
New! Imaging Life Issue 20 now available
January 1, 2025
Ad
PET tracks long-term changes in patients with dementia
January 13, 2025
Micro-PET/CT images of rats. (a) At 24 hours in the control group, F-18 FDG uptake in rats brain tissue was normal, and the PET/CT images were red and white; (b) At 7 days in the control group, F-18 FDG uptake in rats brain tissue were normal, and the PET/CT images were red and white; (c) At 24 hours after TMT exposure, F-18 FDG uptake in rats brain tissue were in a low state, and the PET/CT images were orange and yellow. (d) 7 days after TMT exposure, F-18 FDG uptake in rats brain tissue further decreased, and the PET/CT images appeared yellow and light yellow. There was no significant difference in the uptake of muscle tissue between the model group and the control group, and the PET/CT image was blue. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Scientific Reports.
Animal study shows PET/CT can detect brain damage from TMT poisoning
January 9, 2025
Related Stories
2007 07 17 15 08 50 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 07 17 14 32 28 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 06 25 10 54 15 706
Molecular Imaging
Studies link Alzheimer's to beta-amyloid and potential for new ligand
New! Imaging Life Issue 20 now available
Sponsor Content
New! Imaging Life Issue 20 now available
More in Molecular Imaging
PET/CT can rule out CAV in heart transplant patients
By Will Morton
Cardiac PET/CT scans can effectively rule out moderate to severe cardiac allograft vasculopathy (CAV) in heart transplant patients.
January 17, 2025
Ctca
FAPI-PET shows promise for imaging gastric cancers
By Will Morton
Gallium-68 fibroblast activation protein inhibitor (FAPI) PET/CT is a promising new method for imaging gastric cancer.
January 16, 2025
Fapi Pet Gastric Cancer Thumbnail
PET tracks long-term changes in patients with dementia
By Will Morton
PET imaging can assess brain metabolism changes over time in individuals with prodromal dementia with Lewy bodies (DLB) and probable DLB.
January 13, 2025
Ad
Animal study shows PET/CT can detect brain damage from TMT poisoning
By Will Morton
A feasibility study in rats suggests that PET/CT can detect brain damage caused by trimethyltin chloride (TMT), a hazardous compound widely used in plastics production.
January 9, 2025
Micro-PET/CT images of rats. (a) At 24 hours in the control group, F-18 FDG uptake in rats brain tissue was normal, and the PET/CT images were red and white; (b) At 7 days in the control group, F-18 FDG uptake in rats brain tissue were normal, and the PET/CT images were red and white; (c) At 24 hours after TMT exposure, F-18 FDG uptake in rats brain tissue were in a low state, and the PET/CT images were orange and yellow. (d) 7 days after TMT exposure, F-18 FDG uptake in rats brain tissue further decreased, and the PET/CT images appeared yellow and light yellow. There was no significant difference in the uptake of muscle tissue between the model group and the control group, and the PET/CT image was blue. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Scientific Reports.
New criteria released for amyloid and tau PET imaging
By Will Morton
New appropriate use criteria for amyloid and tau PET imaging of amyloid and tau pathology has been released.
January 8, 2025
A Dpatient
PET scans can decrease unnecessary lymph node procedures
By Will Morton
Negative prostate-specific antigen PET scans can be used to avoid unnecessary pelvic lymph node dissection in certain prostate cancer patients undergoing radical prostatectomies.
January 7, 2025
Psma Pet
PSMA-PET imaging spiked after FDA approval
By Will Morton
Rates of PET prostate cancer imaging increased rapidly after its approval by the U.S. Food and Drug Administration (FDA).
January 6, 2025
Prostate Imaging2
PSMA-PET/CT bests conventional imaging for prostate cancer diagnosis
By Kate Madden Yee
PSMA-PET/CT bests conventional imaging when it comes to identifying high-risk, nonmetastatic, hormone-sensitive prostate cancer, researchers say.
January 3, 2025
Prostate Cancer
Kidneys appear to tolerate Lu-177 treatments
By Will Morton
Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.
December 19, 2024
Kidneys
African American men respond more favorably to Ra-223 therapy
By Will Morton
African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.
December 17, 2024
Prostate Imaging
PET visualizes acute graft vs. host disease
By Will Morton
F-18 fluorothymidine PET can identify early acute gastrointestinal graft versus host disease after patients undergo bone marrow transplants.
December 16, 2024
F-18 FLT-PET imaging of gastrointestinal GVHD. Examples of F-18 FLT uptake in a participant with no GVHD (left) and a participant with acute GVHD and uptake in the jejunum and ileum (right). Arrows denote increased uptake in the GI tract. Image available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of RSNA.
Immuno-PET tracer shows promise in patients with liver cancer
By Will Morton
A new PET radiotracer has the potential for visualizing responses in liver cancer patients undergoing immunotherapy.
December 12, 2024
PET/CT images of F-18 AlF-NOTA-BCP137 in patients with hepatocellular carcinoma (HCC) and immunofluorescence analysis of patient tissues. (A) F-18 AlF-NOTA-BCP137 PET/CT images before and after immunotherapy for patient 1 and patient 2. (B) F-18 AlF-NOTA-BCP137 PET/CT and MR images of patient 3 (left panels) after one cycle of immunotherapy. PET images showed higher uptake by tumor and spleen, and PET result was evaluated as positive; therefore, the patient was considered to be responder to treatment and underwent surgical resection. Representative images of hematoxylin and eosin (HE) staining and multiplex immunofluorescence of CD8 and CD137 (right panels) in HCC tumor and adjacent normal tissues of patient 3 after surgery. Nuclei were stained with 4′,6-diamidino-2-phenylindole. Primary tumors are indicated by white arrows, and increased thyroid uptake is indicated by red arrow in PET images. Image courtesy of the Journal of Nuclear Medicine.
Page 1 of 599
Next Page